Phreesia (NYSE:PHR) Given New $20.00 Price Target at Stephens

Phreesia (NYSE:PHR) had its price target decreased by Stephens from $32.00 to $20.00 in a research note released on Tuesday morning,Benzinga reports. Stephens currently has an overweight rating on the stock.

Other analysts also recently issued reports about the stock. Royal Bank Of Canada initiated coverage on shares of Phreesia in a research report on Friday, January 9th. They issued a “moderate buy” rating and a $26.00 target price for the company. Wall Street Zen downgraded shares of Phreesia from a “strong-buy” rating to a “buy” rating in a report on Sunday, February 8th. DA Davidson reduced their price objective on shares of Phreesia from $35.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Canaccord Genuity Group decreased their price objective on shares of Phreesia from $33.00 to $22.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Barclays lowered their target price on shares of Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 16th. Thirteen investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.00.

Phreesia Stock Down 27.0%

Shares of Phreesia stock opened at $8.33 on Tuesday. The firm has a market cap of $502.28 million, a price-to-earnings ratio of 277.70 and a beta of 0.67. The stock has a 50-day simple moving average of $12.36 and a 200-day simple moving average of $17.57. Phreesia has a 52-week low of $7.77 and a 52-week high of $32.76. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.44 and a quick ratio of 2.44.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). The firm had revenue of $127.07 million during the quarter, compared to analyst estimates of $126.75 million. Phreesia had a return on equity of 3.33% and a net margin of 0.48%.The company’s quarterly revenue was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.11) EPS. On average, equities research analysts expect that Phreesia will post -1.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, General Counsel Allison C. Hoffman sold 6,585 shares of the company’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $112,010.85. Following the completion of the sale, the general counsel directly owned 174,762 shares of the company’s stock, valued at approximately $2,972,701.62. This represents a 3.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Balaji Gandhi sold 8,009 shares of the firm’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $136,233.09. Following the completion of the transaction, the chief financial officer owned 156,231 shares in the company, valued at $2,657,489.31. The trade was a 4.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 70,358 shares of company stock worth $1,123,569. 5.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Phreesia

A number of hedge funds have recently bought and sold shares of PHR. Royal Bank of Canada boosted its holdings in Phreesia by 208.8% during the first quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock valued at $617,000 after acquiring an additional 16,309 shares during the period. AQR Capital Management LLC increased its stake in shares of Phreesia by 471.2% in the first quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock worth $4,090,000 after purchasing an additional 132,015 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Phreesia by 3.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock worth $1,599,000 after purchasing an additional 2,158 shares during the period. NewEdge Advisors LLC lifted its position in shares of Phreesia by 262.7% during the 1st quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock worth $395,000 after purchasing an additional 11,181 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Phreesia by 0.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock worth $15,336,000 after purchasing an additional 2,402 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors.

More Phreesia News

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Quarter results showed revenue growth and improved cash generation, with management flagging free cash flow and adjusted EBITDA milestones reached — evidence the business is profitable and generating cash. Business Wire: Phreesia Announces Fourth-Quarter Fiscal 2026 Results
• Neutral Sentiment: Several firms reaffirmed neutral/hold ratings but cut price targets, reflecting mixed conviction — e.g., JPMorgan (neutral, PT $16 from $24), Robert W. Baird (neutral, PT $10 from $25), Citigroup (neutral, PT $10 from $25), and Truist (hold, PT $11 from $24). These actions compress near-term upside expectations even where conviction remains. Benzinga: Why Is Phreesia Stock Sinking Tuesday?
• Negative Sentiment: Management cut FY27 revenue guidance to $510–$520M (from $545–$559M), citing reduced visibility into pharma client spending and weaker second-half commitments — the primary catalyst for the selloff and for multiple analyst downgrades/price-target reductions. Benzinga: Guidance cut explained
• Negative Sentiment: Major brokers sharply trimmed targets and/or ratings (examples: Stephens cut PT to $20 but kept overweight; BMO to $14/outperform; Canaccord to $22/buy; Needham to $14/buy), increasing near-term downside pressure despite some upbeat long-term views. Benzinga: Analyst price target updates
• Negative Sentiment: Market reaction: shares plunged and hit fresh lows on the guidance cut with unusually high volume, signaling broad investor de-risking and driving further volatility. MarketWatch: Shares touch all-time lows

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.